XML 21 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Trade receivables and other current assets | 6 Months Ended
--- | ---
Jun. 30, 2025
Subclassifications of assets, liabilities and equities [abstract] |
Trade receivables and other current assets | Trade receivables and other current assets 8.1 TRADE RECEIVABLES
| As of
(in thousands of euros) | June 30, 2025 |  | December 31, 2024
Trade receivables | 1,837 |  |  | 2,977 |
Trade receivables | 1,837 |  |  | 2,977 |
As of June 30, 2025, trade receivables balance mainly relates to Janssen revenue not yet collected, which is comprised of product supplies for 1.7 million. 8.2 OTHER CURRENT ASSETS Other current assets break down as follows:
| As of
(in thousands of euros) | June 30, 2025 |  | December 31, 2024
Research tax credit receivable | 4,792 |  |  | 3,369 |
VAT receivable | 1,185 |  |  | 1,104 |
Prepaid expenses | 1,925 |  |  | 3,195 |
Other receivables | 1,332 |  |  | 1,085 |
Other current assets | 9,234 |  |  | 8,753 |
As of June 30, 2025, €1.9 million prepaid expenses mainly relate to research agreements with MD Anderson for €1.1 million as compared to €1.2 million as of December 31, 2024, €0.8 million related to invoices received for third party services beyond the current closing period, mainly related to IT, insurance and other invoices related to annual administrative contracts as compared to €1.1 million as of December 31, 2024, and €46 thousand related to purchases of clinical product not yet consumed as of closing date as compared to €0.6 million as of December 31, 2024, this significant decrease is explained by the sales dynamics of clinical products sold. Other receivables increased by €0.2 million and mainly comprised of advance payments to suppliers amounting of €1.3 million as of June 30, 2025, as compared to €1.1 million as of December 31, 2024. Most of these advance payments have been made to Contract Research Organization (CRO) and to Clinical Services Providers in connection with the execution of the clinical trial NANORAY-312. Research tax credit The Company is eligible for the Research Tax Credit - CIR (Crédit d’Impôt Recherche) issued by the French and U.S. tax authorities. The change in research tax credit receivables breaks down as follows:
(in thousands of euros) |
Receivable as of December 31, 2024 | 3,369 |
2025 research tax credit – Nanobiotix S.A. (1) | 1,616 |
2025 research tax credit – Nanobiotix Corp (1) | (69) |
Receipt of 2024 research tax credit - Nanobiotix Corp | (124) |
Receivable as of June 30, 2025 | 4,792 |
(1) See Note 16 - Revenue and other income.

X
- References No definition available. + Details
Name: | ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Trade Receivables And Other Current Assets + References No definition available. + Details
Name: | nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock
Namespace Prefix: | nbx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration